0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders

Not currently available

Progress Medicinal Chem Pmc36h (Electronic book text)
Progress Medicinal Chem Pmc36h (Electronic book text): Frank D. King, A.W. Oxford, unknownauthor, F.D. King
Progress Medicinal Chem Pmc36h (Electronic book text): Frank D. King, A.W. Oxford, unknownauthor, F.D. King

Share your images

Progress Medicinal Chem Pmc36h (Electronic book text)

Frank D. King, A.W. Oxford, unknownauthor, F.D. King

 (sign in to rate)

Bookmark and Share

We have no sources for this product at present. If you add this to your wishlist we will let you know should it become available to order.

The six chapters presented in this volume review recent advances in important areas of medicinal chemistry. Chapter 1 describes the rational drug design of inhibitors of the influenza virus enzyme, sialidase, from which zanamivir was identified. This compound is representative of a new generation of agents for the treatment of human influenza infections. Nonpeptide small molecule fibrinogen antagonists are reviewed in chapter 2, indicating the extent of progress to identify compounds with good oral pharmacokinetics. The clinical trials of these potent antithrombotic agents are giving encouraging results in angioplasty and unstable angina and as an adjunct to thrombolysis therapy in myocardial infarction. Combinatorial chemistry, one of the most rapidly evolving techniques for drug discovery, is already the subject of many reviews but most are concerned with synthetic methodology. In contrast, chapter 3 considers the value of combinatorial chemistry to the medicinal chemist by reviewing the scope of its application to therapeutically important targets and reveals there is much progress to report. Advances in the molecular biology and pharmacology of the neurotransmitter, GABA, have established there is considerable heterogeneity in GABAa receptors, the receptors known to be modulated by all the clinically effective benzodiazepine anxiolytics. The consequent surge of activity to find anxiolytic agents which are more selective and possess fewer side-effects than the early benzodiazepines has led to the synthesis of a variety of novel structures. One such series of pyrido 1,2-a]benzimidazoles is described in chapter 4. There is good evidence to suggest that cyclooxygenase-2(COX-2) inhibitors will have important advantages over conventional non-steroidal anti-inflammatory drugs in arthritic disorders, and may be of value in Alzheimer's disease. The numerous compounds that exhibit COX-2 inhibitory activity are reviewed systematically in chapter 5. One of the most recent technologies to be developed is that of molecularly imprinted polymers. These materials have considerable potential in a variety of settings, including chromatographic separation of chiral molecules, and in the high throughput screening of complex mixtures such as combinatorial libraries. A survey of this field is given in chapter 6.

General

Imprint: Elsevier Science Ltd
Country of origin: United States
Release date: 1999
Editors: Frank D. King • A.W. Oxford • unknownauthor • F.D. King
Format: Electronic book text
ISBN-13: 978-1-281-71584-5
Barcode: 9781281715845
Categories: Promotions
Books > Medicine > Clinical & internal medicine > Diseases & disorders
Books > Medicine > Clinical & internal medicine > Diseases & disorders > General
LSN: 1-281-71584-0

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Loyalty partners